News & Updates

Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease

Calico starts phase 1b study evaluating safety, tolerability and pharmacokinetics of eIF2B activator.

The VWM Consortium designed a 'core clinical trial protocol', aimed to serve as a template for industry-sponsored clinical trials in VWM.

In an end-of-the-year countdown on Facebook, the scientific journal ‘Neurology: Genetics’ stated that their #2 most read paper of 2022 is the VWM Consortium paper on therapy trial design.

This public statement from advocates of the VWM community demonstrates their close partnership with the VWM consortium in optimizing clinical trial design and future patient participation.

The first trial participant was included on May 31st 2021, in this update we reflect on the first year of the clinical trial.

The first paper published by the VWM consortium & patient associations describes recommendations for VWM clinical trial design.

We are pleased to announce that the first three VWM patients have been enrolled in the study and more patients will follow soon.

This conference focuses on providing scientific information to keep families informed of progress in the leukodystrophy field. Please join our presentation live.

Amsterdam UMC developed two mouse models for VWM. These mice harbor VWM genetic mutations, which result in a phenotype similar to human VWM patients.